Key Facts About Hormone Therapy

  • Hormone therapy (endocrine therapy) blocks or lowers hormones that fuel certain cancers, primarily breast and prostate cancer
  • Approximately 70–80% of breast cancers are hormone receptor-positive and eligible for hormone therapy
  • Hormone therapy for breast cancer is typically taken for 5–10 years to reduce recurrence risk
  • Androgen deprivation therapy (ADT) for prostate cancer can be given as injections, pills, or through surgery
  • Newer combinations with CDK4/6 inhibitors have significantly improved outcomes in metastatic breast cancer

How Hormones Fuel Cancer Growth

Certain cancers depend on naturally occurring hormones to grow. In hormone receptor-positive breast cancer, estrogen and progesterone bind to receptors on cancer cells, activating genes that promote cell growth and division. In prostate cancer, testosterone and its more potent derivative dihydrotestosterone (DHT) fuel cancer cell proliferation through the androgen receptor.

Hormone therapy works by either reducing the body’s production of these hormones, blocking the hormones from reaching cancer cells, or altering the hormones so they can no longer stimulate growth. Unlike chemotherapy, which kills cells directly, hormone therapy is primarily a growth-suppression strategy — it starves cancer cells of the hormonal signals they need to survive and multiply.

Because hormone therapy targets a specific growth pathway rather than all dividing cells, its side effect profile is generally more manageable than chemotherapy, though treatment duration is much longer and long-term effects require careful monitoring.

Hormone Therapy for Breast Cancer

Hormone receptor-positive (HR+) breast cancer — defined by the presence of estrogen receptors (ER+) and/or progesterone receptors (PR+) on tumor cells — accounts for roughly 70–80% of all breast cancers. Treatment choice depends on menopausal status, cancer stage, and individual risk factors.

Tamoxifen

Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen from binding to receptors on breast cancer cells. It has been a cornerstone of breast cancer treatment for over 40 years and can be used in both premenopausal and postmenopausal women. Standard treatment is 20 mg daily by mouth. Tamoxifen reduces the risk of breast cancer recurrence by approximately 40–50% and the risk of contralateral breast cancer by about 50%.

Tamoxifen has some estrogen-like effects on other tissues, which can be beneficial (maintaining bone density) or harmful (increasing the risk of uterine cancer and blood clots). The risk of endometrial cancer is small (about 1 in 500 per year) but requires awareness of abnormal vaginal bleeding.

Aromatase Inhibitors (AIs)

Aromatase inhibitors block the enzyme aromatase, which converts androgens into estrogen in fat tissue, muscle, and other non-ovarian sources. Because they do not block ovarian estrogen production, AIs are used only in postmenopausal women or premenopausal women receiving ovarian suppression.

  • Anastrozole (Arimidex): 1 mg daily. The most commonly prescribed AI
  • Letrozole (Femara): 2.5 mg daily. Similar efficacy to anastrozole; some data suggest slight advantages in certain settings
  • Exemestane (Aromasin): 25 mg daily. A steroidal AI with a slightly different mechanism; sometimes used after 2–3 years of tamoxifen as a switch strategy

AIs are modestly more effective than tamoxifen at preventing recurrence in postmenopausal women and are generally preferred as first-line hormone therapy in this group. However, they accelerate bone loss and can cause significant joint and muscle pain (arthralgia/myalgia), which is the most common reason patients discontinue treatment.

Ovarian Suppression

In premenopausal women with higher-risk hormone receptor-positive breast cancer, ovarian suppression (shutting down estrogen production by the ovaries) combined with an aromatase inhibitor or tamoxifen improves outcomes compared to tamoxifen alone. Ovarian suppression is achieved with LHRH agonists such as goserelin (Zoladex) or leuprolide, or rarely through surgical removal of the ovaries (oophorectomy).

CDK4/6 Inhibitor Combinations

The addition of CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) to hormone therapy has become the standard of care for metastatic HR+/HER2– breast cancer. These combinations have approximately doubled progression-free survival compared to hormone therapy alone, and ribociclib has demonstrated significant overall survival benefit. Abemaciclib is also approved in the adjuvant (post-surgery) setting for high-risk early-stage disease.

Breast Cancer Hormone Therapy Timeline Timeline showing typical hormone therapy schedules for breast cancer. Premenopausal women may take tamoxifen for 5 to 10 years, or ovarian suppression plus aromatase inhibitor. Postmenopausal women take an aromatase inhibitor for 5 to 10 years or may switch from tamoxifen after 2 to 3 years. Breast Cancer Hormone Therapy Timeline Year 0 1 2 3 4 5 6 7 8 9 10 Premenopausal Option A: Tamoxifen (5 years) Extended to 10 years (high-risk) Option B: Ovarian suppression + AI (5 years) Postmenopausal Option C: Aromatase Inhibitor (5 years) Extended to 10 years (high-risk) Option D: Tamoxifen (2–3 yr) AI (2–3 yr) Switch strategy (5 yr total) Tamoxifen Aromatase inhibitor Ovarian suppression + AI Optional extension Treatment duration depends on recurrence risk, side effect tolerance, and individual patient factors.
Hormone therapy for breast cancer typically lasts 5 to 10 years. The specific drug and duration depend on menopausal status and recurrence risk. High-risk patients may benefit from extended treatment up to 10 years.

Hormone Therapy for Prostate Cancer

Prostate cancer cells depend on androgens (primarily testosterone and DHT) for growth. Hormone therapy for prostate cancer, known as androgen deprivation therapy (ADT), aims to reduce androgen levels or block androgen activity at the receptor level.

LHRH Agonists and Antagonists

Luteinizing hormone-releasing hormone (LHRH) agonists (leuprolide, goserelin, triptorelin) initially cause a surge in testosterone before suppressing production. LHRH antagonists (degarelix, relugolix) suppress testosterone without the initial surge. Both approaches reduce testosterone to castrate levels (<50 ng/dL). These drugs are given as periodic injections (monthly, quarterly, or every six months) or, in the case of relugolix, as a daily oral pill.

Anti-Androgens

Anti-androgens block testosterone from reaching the androgen receptor. First-generation anti-androgens (bicalutamide, flutamide) are sometimes added to LHRH agonists. Second-generation anti-androgens are far more potent:

  • Enzalutamide (Xtandi): Blocks the androgen receptor and prevents it from entering the cell nucleus. Approved for both castration-sensitive and castration-resistant prostate cancer
  • Apalutamide (Erleada): Similar mechanism to enzalutamide. Approved for non-metastatic and metastatic castration-resistant prostate cancer
  • Darolutamide (Nubeqa): A structurally distinct anti-androgen with fewer central nervous system side effects. Approved for non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive disease

Abiraterone (Zytiga)

Abiraterone inhibits CYP17A1, an enzyme critical for androgen synthesis in the testes, adrenal glands, and tumor tissue. It is taken as a daily oral pill with prednisone and is approved for both castration-sensitive and castration-resistant prostate cancer. Abiraterone is typically used in combination with ADT.

Drug Class Mechanism Key Examples Administration
LHRH agonists Suppress testicular testosterone production Leuprolide, goserelin Injection (monthly–6 monthly)
LHRH antagonists Suppress testosterone without initial surge Degarelix, relugolix Injection or daily pill
Anti-androgens (2nd gen) Block androgen receptor Enzalutamide, apalutamide, darolutamide Daily oral pill
CYP17 inhibitors Block androgen synthesis Abiraterone Daily oral pill + prednisone

Side Effects of Hormone Therapy

Because hormone therapy alters fundamental hormonal balance, side effects reflect the loss of estrogen (in breast cancer treatment) or testosterone (in prostate cancer treatment). Most side effects are manageable but require proactive monitoring and intervention.

Breast Cancer Hormone Therapy Side Effects

  • Hot flashes: The most common side effect, affecting up to 80% of patients. May improve over time; venlafaxine or gabapentin can provide relief
  • Joint and muscle pain: Particularly common with aromatase inhibitors (up to 50% of patients). Regular exercise, maintaining healthy weight, and switching AI brands may help
  • Bone loss (osteoporosis): Aromatase inhibitors and ovarian suppression accelerate bone loss. Baseline and periodic DEXA scans are recommended, along with calcium, vitamin D, and bisphosphonates or denosumab if needed
  • Vaginal dryness and sexual dysfunction: Common with both tamoxifen and AIs; non-hormonal moisturizers and lubricants can help
  • Mood changes and depression: Monitor mental health; counseling and antidepressants may be appropriate
  • Blood clots and uterine cancer: Tamoxifen-specific risks; report abnormal bleeding immediately

Prostate Cancer Hormone Therapy Side Effects

  • Hot flashes: Affect up to 80% of men on ADT
  • Sexual dysfunction: Loss of libido and erectile dysfunction are nearly universal with ADT
  • Bone loss: Testosterone deprivation accelerates osteoporosis; DEXA scans and bone-protecting agents are recommended
  • Metabolic syndrome: Weight gain, increased body fat, insulin resistance, and elevated cholesterol
  • Cardiovascular risk: ADT may increase the risk of heart disease and diabetes; cardiovascular monitoring and lifestyle modifications are essential
  • Fatigue and muscle loss: Regular resistance exercise can help maintain muscle mass and reduce fatigue
  • Cognitive changes: Some studies suggest ADT may affect memory and concentration

Managing Long-Term Hormone Therapy

  • Do not stop hormone therapy without discussing with your oncologist, even if side effects are bothersome — adherence is critical for preventing recurrence
  • Get baseline DEXA scan before starting and repeat every 1–2 years
  • Maintain regular weight-bearing exercise and resistance training
  • Ensure adequate calcium (1,200 mg/day) and vitamin D (1,000–2,000 IU/day)
  • Monitor cardiovascular risk factors: blood pressure, cholesterol, blood sugar
  • Report new symptoms promptly — dose adjustments or drug switches can often improve quality of life

Treatment Duration

Hormone therapy duration depends on cancer type, stage, and risk level:

  • Early-stage breast cancer: Minimum 5 years; extended to 7–10 years for higher-risk patients. The decision to extend treatment weighs the recurrence reduction benefit against cumulative side effects
  • Metastatic breast cancer: Continued indefinitely (often combined with CDK4/6 inhibitors) until disease progression or intolerable side effects
  • Localized prostate cancer (with radiation): 6 months to 2–3 years of ADT, depending on risk category
  • Metastatic prostate cancer: ADT is typically continued indefinitely, often intensified with abiraterone, enzalutamide, or other agents

Related Resources

Last reviewed: March 2026. This information is for educational purposes only and is not a substitute for professional medical advice. Always consult your oncologist about your specific treatment plan.